- Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
- Recursion to Participate in Upcoming Investor Conferences
- Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
- Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
- Recursion to Participate in Upcoming Investor Conference
- Recursion Publishes Annual Environmental, Social and Governance Report
- Recursion Announces Plans to Open New Office in London
- Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
- Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
- Recursion to Host Public L(earnings) Call on February 27
More ▼
Key statistics
On Friday, Recursion Pharmaceuticals Inc (RXRX:NSQ) closed at 8.84, 94.29% above the 52 week low of 4.55 set on May 03, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.24 |
---|---|
High | 9.40 |
Low | 8.70 |
Bid | 8.84 |
Offer | 8.88 |
Previous close | 8.79 |
Average volume | 4.74m |
---|---|
Shares outstanding | 237.52m |
Free float | 217.17m |
P/E (TTM) | -- |
Market cap | 2.09bn USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼